Protocol Page


	Study ID (Protocol Number)
	CA180-185


	STUDY LOCATIONS*
	Arizona Oncology Associates D.B.A. Hematology Oncology Tucson, AZ 85704 Recruiting	Cancer Care Northwest Spokane, WA 99202 Recruiting
	Cancer Care Centers Of South Texas San Antonio, TX 78217 Recruiting	Central Indiana Cancer Centers Carmel, IN 46032 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
	STUDY OVERVIEW
	The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.